Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma

NCT02495922 is registered in ClinicalTrials.gov with University of Heidelberg Medical Center as lead sponsor.

NCT NCT02495922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02495922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
Lead sponsor
University of Heidelberg Medical Center
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2015
Completion date
June 24, 2021
Enrollment
564 (actual)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma